Accessibility Menu
Protagenic Therapeutics logo

Protagenic Therapeutics(OTC) PTIX

Current Price$0.22
Market Cap$390.30KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2025)-98%
5 Year-100%
1 Year-85%
1 Month-52%
Protagenic Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.222026-07-22
Protagenic Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-17.17%USD 0.262026-07-15
1 month-52.09%USD 0.452026-06-22
3 month-70.21%USD 0.722026-04-23
Year to date-84.91%USD 1.432025-05-05
1 year-84.91%USD 1.432025-05-05
3 year-98.52%USD 14.532023-07-21
5 year-99.69%USD 69.082021-07-23
Since inception-98.06%USD 11.102025-05-19

Protagenic Therapeutics Financials at a Glance

Market Cap

$390.30KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$5.16M

EPS (TTM)

-$4.04

P/E Ratio

-0.05

Dividend

$0.00

Beta (Volatility)

-0.02 (Low)

Price

$0.22

Volume

6

Open

$0.18

Previous Close

$0.22

Daily Range

$0.18 - $0.29

52-Week Range

$0.14 - $1.20

Estimated Earnings Date

Aug 18, 2026

PTIX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Protagenic Therapeutics

Protagenic develops medicines for people with stress-related mental health conditions. Its main drug aims to help those with depression, anxiety, or trauma. The company’s work targets brain stress responses to improve daily life for patients.

Brainy Business: Products and Services

  • PT00114 (Lead Drug Candidate): Synthetic peptide for depression, anxiety, addiction, and post-traumatic stress disorder (PTSD); 0% of revenue as company is pre-revenue.
  • TCAP Research Pipeline: Early-stage compounds exploring similar brain stress pathways; 0% of revenue.
  • Intellectual Property Licensing: Exclusive rights to PT00114 and related technology from the University of Toronto; 0% of revenue.

Growth Spurts: Expansion and Milestones

  • Launched Phase I/IIa clinical trial for PT00114 in September 2023.
  • Reverse stock split (1-for-14) in May 2025 to maintain Nasdaq listing.
  • Raised $395,474 in April 2025 through new share issuance.

What Makes Protagenic Stand Out

Protagenic’s drug targets a unique brain pathway not addressed by most current treatments. The company holds exclusive global rights to its main technology. Its research is built on academic partnerships and patent protection.

Five Things You Need to Know

  • No revenue reported for Q2 2025, Q2 2024, or Q2 2023.
  • Net loss was $1.44 million in Q1 2025, down approximately 16% from Q1 2024.
  • Cash was $872,960 as of March 31, 2025, down about 53% from December 2024.
  • Research and development spending fell about 40% year-over-year in Q1 2025.
  • Company needs new funding by Q3 2025 to continue operations.

Bottom Line

Protagenic is a single-product biotech focused on mental health drug development. Its future depends on clinical progress and securing new funding.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

5

CEO

Barrett Evans

Website

www.protagenic.com

Headquarters

Santa Barbara, CA 93101, US

PTIX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

184.88%

Return on Capital

-764.05%

Return on Assets

-241.84%

Earnings Yield

-20.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$390.30KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.81M

Volume

6

Avg. Volume

7.91K

Financials (TTM)

Gross Profit

-$37.72K

Operating Income

-$5.83M

EBITDA

-$8.01M

Operating Cash Flow

-$4.14M

Capital Expenditure

-$3.00

Free Cash Flow

-$4.14M

Cash & ST Invst.

$2.21M

Total Debt

$3.16M

Protagenic Therapeutics Performance Analysis

Protagenic Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
Protagenic Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-31100.0%
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Protagenic Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -17.18N/A
20222022-12-31USD -11.53-32.9%
20232023-12-31USD -16.1139.8%
20242024-12-31USD -15.79-2.0%
Protagenic Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-31-1045.8%
Q22025-06-3050.2%
Q32025-09-3065.7%
Q42025-12-31342.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

+100.0%

Gross Profit

$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

$390.30KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$390.30K

N/A

Employees

1

N/A

Net Income

$2.21M

+242.3%

EBITDA

-$912.53K

+40.8%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$2.21M

+20.4%

Total Debt

$3.16M

N/A

Accounts Receivable

$41.52K

N/A

Inventory

$1.07K

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$3.16M

N/A

Return on Assets

-2.42%

N/A

Return on Invested Capital

1.24%

N/A

Free Cash Flow

-$410.43K

+49.9%

Operating Cash Flow

-$410.42K

+49.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SPRCSciSparc Ltd.
$4.84+1.89%
CARMCarisma Therapeutics, Inc.
$0.00+7.14%
LIPOLipella Pharmaceuticals Inc.
$0.03+0.00%
PBMPsyence Biomedical Ltd.
$2.95-5.14%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$23.04+0.04%
SMCISuper Micro Computer
$30.56+0.20%
AALAmerican Airlines Group
$14.79-0.03%
NUNu Holdings
$14.51+0.01%

Questions About PTIX

What is the current price of Protagenic Therapeutics?

Protagenic Therapeutics is trading at $0.22 per share.

What is the 52-week range for Protagenic Therapeutics?

Over the past 52 weeks, Protagenic Therapeutics has traded between $0.14 and $1.20.

How much debt does Protagenic Therapeutics have?

As of the most recent reporting period, Protagenic Therapeutics reported total debt of $4.00M.

How much cash does Protagenic Therapeutics have on hand?

Protagenic Therapeutics reported $2.21M in cash and cash equivalents in its most recent financial results.

What is Protagenic Therapeutics’s dividend yield?

Protagenic Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services